ReviewInternational journal of molecular sciences2021
Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Effects of yoga interventions on Anti-Müllerian hormone, androgen levels, and metabolic parameters in women with polycystic ovary syndrome: a systematic review.BMC complementary medicine and therapies · 2026Pooled it
- Anti-Müllerian hormone levels and live birth rate in polycystic ovary syndrome patients undergoing assisted reproductive technology: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Bibliometric analysis of the research on anti-Müllerian hormone and polycystic ovary syndrome: current status, hotspots, and trends.Frontiers in reproductive health · 2025Pooled it
- Impact of mean arterial pressure on reproductive endocrine characteristics in infertile patients with polycystic ovary syndrome: a secondary analysis of a randomized clinical trial.Frontiers in endocrinology · 2025Trial
- Vitamin D status and inflammatory Interleukins in women with and without polyendocrine metabolic ovarian syndrome: a cross-sectional exploratory study.Annals of medicine · 2026Article
- Hardened ground: ECM stiffness as a unifying biomechanical driver of reproductive stem cell aging.Biogerontology · 2026Review
- Subtype matters: ovarian endometriosis impairs ovarian reserve and embryo quality-should these patients consider fertility preservation?Archives of gynecology and obstetrics · 2026Article
- Incident endometriosis diagnosis and AMH: how surgical staging and typology relate to serum AMH levels.American journal of obstetrics and gynecology · 2026Article
- Spontaneous Premature Ovarian Insufficiency: Methods Under Research for Infertility Treatment.Journal of clinical medicine · 2026Review
- Diagnostic Criteria and Genetic Basis of Polycystic Ovary Syndrome: A Narrative Review.Metabolites · 2026Review
- The effects ofResearch in pharmaceutical sciences · 2026Article
- Anti-Müllerian Hormone Levels Across Phenotypes in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.Journal of the Endocrine Society · 2026Review
- Review
- Comment on "AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles".Reproductive biology and endocrinology : RB&E · 2026Article
- Age- and BMI-stratified assessment of serum anti-Müllerian hormone as a biomarker for polycystic ovary syndrome diagnosis in Chinese women.BMC endocrine disorders · 2026Article
- Anti-Müllerian hormone in relation to adiposity and metabolic indices in polyendocrine metabolic ovarian syndrome.Frontiers in endocrinology · 2026Article
- Fetal growth in PCOS pregnancies: dynamic evidence of restriction and the modifying role of ART.Frontiers in medicine · 2026Article
- Unraveling the Complexity of Polycystic Ovary Syndrome: Biomarkers for Diagnosis, Prognosis, and Treatment.Current pharmaceutical design · 2026Review
- Reconsidering antral follicle changes in the DHEA-induced PCOS model: the overlooked role of AMH and methodological variability.Journal of ovarian research · 2025Review
- Comparative effects of streptozotocin, dehydroepiandrosterone and letrozole with high fat diet on ovarian injury induction and functional impairment.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women. It is characterized by chronic anovulation, hyperandrogenism, and the presence of polycystic ovary in ultrasound examination. PCOS is specified by an increased number of follicles at all growing stages, mainly seen in the preantral and small antral follicles and an increased serum level of Anti-Müllerian Hormone (AMH). Because of the strong correlation between circulating AMH levels and antral follicle count on ultrasound, Anti-Müllerian Hormone has been proposed as an alternative marker of ovulatory dysfunction in PCOS. However, the results from the current literature are not homogeneous, and the specific threshold of AMH in PCOS and PCOM is, therefore, very challenging. This review aims to update the current knowledge about AMH, the pathophysiology of AMH in the pathogenesis of PCOS, and the role of Anti-Müllerian Hormone in the treatment of this syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.